BioSpace News Archive

Elevation Oncology, Inc. today announced that it has entered into an exclusive license agreement with CSPC Megalith Biopharmaceutical Co., Ltd, a subsidiary of CSPC Pharmaceutical Group Limited (CSPC; HKEX: 01093) to develop and commercialize EO-3021.

Evofem Biosciences, Inc., (Nasdaq: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the second quarter ended June 30, 2022 as follows.

Neovasc Inc. ( NASDAQ , TSX : NVCN), will report financial results for the quarter ended June 30, 2022 on Thursday, August 11, 2022.

Iroquois Capital Management, LLC announced that it has filed preliminary consent materials with the SEC regarding its solicitation of written consents from stockholders in lieu of a stockholder meeting to reconstitute a majority of the PharmaCyte Board of Directors with its slate of highly qualified nominees.

Micro-Tech Endoscopy USA, an industry leader in the development of diagnostic and therapeutic devices in the gastroenterology space, has announced a distribution partnership with innovator in pulmonology, Thoracent.

OptraSCAN® a leading end-to-end digital pathology solution provider, announced that it has received CE-IVDR marking for the OS-Ultra™ scanners, its high-performance product line of brightfield scanners at an extremely affordable price point, including pay-per-scan based OPEX models.

Emergex Vaccines Holding Limited, a clinical stage biotechnology company addressing major global infectious diseases through the development of fully synthetic CD8+ T cell Adaptive Vaccines, announces the manufacture of its universal/pandemic influenza vaccine, ready for Phase I clinical trials.

argenx SE announced that an extraordinary general meeting of shareholders will be held at 18:30 PM CEST on Thursday, September 8, 2022 at the offices of Freshfields Bruckhaus Deringer LLP, Strawinskylaan 10, 1077 XZ in Amsterdam, the Netherlands.

Theravance Biopharma, Inc. will report its second quarter 2022 financial results and provide a business update after market close on Thursday, August 4, 2022.

RepliCel Life Sciences Inc. is pleased to announce the completion, last week, of an inspection of RepliCel’s NBDS cell therapy manufacturing at its Austrian contract manufacturing facility owned and operated by Innovacell KK.